Compare VR perimetry to HFA/OCT
- Researchers highlighted new evidence that head-mounted VR perimetry can track glaucomatous field loss with repeatability close to conventional Humphrey testing. - The useful detail is not “VR beats HFA.” It’s that repeatability looks good enough for follow-up, but device outputs still are not interchangeable. - That matters because glaucoma care needs both function and structure, and OCT correlation still anchors decisions in moderate and advanced disease.
Visual field testing is one of the bottlenecks in glaucoma care. It is slow, fatiguing, and noisy in exactly the wrong way — a patient gets one bad run, and suddenly the chart looks worse than the optic nerve does. That is why virtual-reality perimetry keeps coming up. A headset could make testing more portable, more comfortable, and easier to repeat. The real question is whether it is reliable enough to trust when the stakes are progression and vision loss. ### What is VR perimetry, exactly? It is standard automated perimetry reworked into a head-mounted display. Instead of sitting at a bowl perimeter like the Humphrey Field Analyzer, the patient wears a headset that presents stimuli in a controlled visual environment. Different systems use different hardware and algorithms, but the pitch is similar — portability, less dependence on a dark room and technician setup, and the possibility of clinic-side or even home testing. (aao.org) ### Why is Humphrey still the benchmark? Because Humphrey is the language glaucoma clinics already speak. Treatment decisions, progression software, and years of longitudinal follow-up are built around HFA outputs like mean deviation and pattern standard deviation. The catch is that even Humphrey fields are noisy, especially as glaucoma gets worse. In moderate and advanced disease, test–retest variability becomes a serious problem, which is exactly why any new perimeter has to prove repeatability before anything else. (aao.org) ### So what changed here? The newer wave of studies is moving past simple “can patients finish the test?” questions and into clinical comparability. A 2025 systematic review pulled 14 glaucoma studies across 10 VR perimetry devices and landed in a cautious place: the overall signal is promising, but the big missing piece is still robust repeatability data across devices and protocols. That is why any fresh report emphasizing test–retest performance in moderate to advanced glaucoma gets attention — it is addressing the exact gap the field has been calling out. (aaojournal.org) ### Does VR match Humphrey one-to-one? Not really — and that is the wrong standard anyway. Even when studies show similar global indices or strong agreement, device outputs are affected by different luminance settings, stimulus scaling, fixation monitoring, and thresholding strategies. One comparative study in glaucoma and healthy eyes found broadly comparable clinical outputs, but also showed that direct point-by-point equivalence is messy. Basically, “close enough for clinical use” is not the same thing as “numerically interchangeable.” (journals.plos.org) ### Where does OCT fit into this? OCT is the structural side of the story. Perimetry tells you what function is lost; OCT shows retinal nerve fiber layer and ganglion cell damage. In advanced glaucoma, structure can hit a floor and function can get noisier, so neither test should be read alone. That is why a repeatable VR field is useful, but still not something you would interpret in isolation. If the field worsens and OCT, disc appearance, and the clinical picture do not line up, you pause before escalating treatment. (pmc.ncbi.nlm.nih.gov) ### Why could trainees care? Because workflow matters. A lighter, headset-based test could reduce room constraints, simplify setup, and make repeat testing easier for patients who struggle with conventional perimetry. AAO’s own glaucoma coverage has been upbeat about those practical advantages — especially portability and reduced technician burden — but also blunt that the evidence is not strong enough yet to replace conventional perimetry outright. (aaojournal.org) ### What is the catch? The catch is validation. “Promising” is not the same as plug-and-play. Different VR devices are not one thing, and glaucoma follow-up depends on consistency over years, not a clever first impression. If a clinic adopts VR perimetry, the safest use case today is as a complementary functional test with careful correlation to HFA history and OCT structure, not as a wholesale swap. (aao.org) ### Bottom line? VR perimetry is getting closer to being clinically boring — and that is good news. In glaucoma, boring means repeatable, interpretable, and good enough to trust over time. The field is not fully there yet, but it is clearly moving from gadget status toward a real monitoring tool. (journals.plos.org)
